MX2020003737A - Potenciador para celulas t o celulas b que tienen funcion de memoria, inhibidor de recurrencia de tumor maligno, e inductor para inducir la funcion de memoria en celulas t o celulas b. - Google Patents
Potenciador para celulas t o celulas b que tienen funcion de memoria, inhibidor de recurrencia de tumor maligno, e inductor para inducir la funcion de memoria en celulas t o celulas b.Info
- Publication number
- MX2020003737A MX2020003737A MX2020003737A MX2020003737A MX2020003737A MX 2020003737 A MX2020003737 A MX 2020003737A MX 2020003737 A MX2020003737 A MX 2020003737A MX 2020003737 A MX2020003737 A MX 2020003737A MX 2020003737 A MX2020003737 A MX 2020003737A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- memory function
- nucleic acid
- malignant tumor
- enhancer
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 230000006386 memory function Effects 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 239000003623 enhancer Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000000411 inducer Substances 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 102000000704 Interleukin-7 Human genes 0.000 abstract 4
- 108010002586 Interleukin-7 Proteins 0.000 abstract 4
- 229940100994 interleukin-7 Drugs 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 3
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464421—Receptors for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un objeto de la presente invención es proporcionar un potenciador para células T endógenas o células B que tienen una función de memoria y un inhibidor de recurrencia de tumor maligno para continuar rechazando el tumor maligno durante un largo periodo de tiempo; un potenciador para células T o células B que tienen una función de memoria en un sujeto de administración, que comprende un vehículo de administración de ácido nucleico, un ácido nucleico que codifica interleucina-7 (IL-7) y un ligando 19 (motivo C-C) de quimiocina que codifica el ácido nucleico (CCL19), y se prepara un inductor para inducir una función de memoria en células T o células B en un sujeto de administración; además, se prepara un inhibidor de recurrencia de tumor maligno que comprende un vehículo de administración de ácido nucleico, un ácido nucleico que codifica interleucina-7 (IL-7) y un ácido nucleico que codifica CCL19.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017196718 | 2017-10-10 | ||
PCT/JP2018/037608 WO2019073973A1 (ja) | 2017-10-10 | 2018-10-09 | メモリー機能を有するt細胞又はb細胞の増強剤、悪性腫瘍再発抑制剤、及びt細胞又はb細胞にメモリー機能を誘導する誘導剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003737A true MX2020003737A (es) | 2020-08-03 |
Family
ID=66100816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003737A MX2020003737A (es) | 2017-10-10 | 2018-10-09 | Potenciador para celulas t o celulas b que tienen funcion de memoria, inhibidor de recurrencia de tumor maligno, e inductor para inducir la funcion de memoria en celulas t o celulas b. |
Country Status (16)
Country | Link |
---|---|
US (1) | US11617765B2 (es) |
EP (2) | EP4265634A3 (es) |
JP (2) | JP7232447B2 (es) |
KR (1) | KR20200068661A (es) |
CN (1) | CN111163758A (es) |
AU (2) | AU2018349889B2 (es) |
BR (1) | BR112020006746A2 (es) |
CA (1) | CA3075886A1 (es) |
CL (1) | CL2020000950A1 (es) |
ES (1) | ES2970282T3 (es) |
IL (2) | IL273689B2 (es) |
MX (1) | MX2020003737A (es) |
PH (1) | PH12020550241A1 (es) |
SG (1) | SG11202003252TA (es) |
WO (1) | WO2019073973A1 (es) |
ZA (1) | ZA202000986B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020006666A (es) * | 2017-12-24 | 2020-08-31 | Noile Immune Biotech Inc | Celula inmunocompetente que expresa una molecula de superficie celular que reconoce especificamente la mesotelina humana, il-7 y ccl19. |
CA3156231A1 (en) | 2019-10-28 | 2021-05-06 | Koji Tamada | Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product |
WO2021193081A1 (ja) * | 2020-03-23 | 2021-09-30 | 国立大学法人東海国立大学機構 | 1型単純ヘルペスウイルス |
CN111849910B (zh) * | 2020-05-27 | 2021-06-15 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
CN114717203B (zh) * | 2020-12-22 | 2023-06-27 | 广东东阳光药业有限公司 | 一种hIL7/hCCL19双基因重组溶瘤病毒及其制备方法和用途 |
WO2023007431A1 (en) * | 2021-07-29 | 2023-02-02 | Takeda Pharmaceutical Company Limited | Engineered immune cell that specifically targets mesothelin and uses thereof |
CN113832115A (zh) * | 2021-08-25 | 2021-12-24 | 居颂光 | 融合基因ril-7联合ccl19重组溶瘤牛痘病毒及其在制备抗肿瘤药物中的应用 |
GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
JP3867968B2 (ja) | 2002-07-08 | 2007-01-17 | 関西ティー・エル・オー株式会社 | 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス |
CA2795695A1 (en) * | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
BR112013017096A2 (pt) | 2011-01-04 | 2020-09-01 | Jennerex Inc. | composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
JP5716759B2 (ja) | 2013-01-09 | 2015-05-13 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子の製造方法 |
JP5701442B1 (ja) | 2014-09-05 | 2015-04-15 | 関西ペイント株式会社 | カチオン電着塗料組成物 |
HUE060047T2 (hu) | 2014-10-09 | 2023-01-28 | Univ Yamaguchi | CAR expressziós vektor és CAR-t expresszáló T-sejtek |
KR102495308B1 (ko) | 2016-03-17 | 2023-02-06 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 |
-
2018
- 2018-10-09 KR KR1020207009950A patent/KR20200068661A/ko not_active Application Discontinuation
- 2018-10-09 BR BR112020006746-6A patent/BR112020006746A2/pt unknown
- 2018-10-09 IL IL273689A patent/IL273689B2/en unknown
- 2018-10-09 MX MX2020003737A patent/MX2020003737A/es unknown
- 2018-10-09 CA CA3075886A patent/CA3075886A1/en active Pending
- 2018-10-09 SG SG11202003252TA patent/SG11202003252TA/en unknown
- 2018-10-09 IL IL305898A patent/IL305898B1/en unknown
- 2018-10-09 EP EP23187186.4A patent/EP4265634A3/en active Pending
- 2018-10-09 AU AU2018349889A patent/AU2018349889B2/en active Active
- 2018-10-09 US US16/754,645 patent/US11617765B2/en active Active
- 2018-10-09 CN CN201880062891.XA patent/CN111163758A/zh active Pending
- 2018-10-09 JP JP2019548200A patent/JP7232447B2/ja active Active
- 2018-10-09 EP EP18866437.9A patent/EP3695846B1/en active Active
- 2018-10-09 WO PCT/JP2018/037608 patent/WO2019073973A1/ja active Application Filing
- 2018-10-09 ES ES18866437T patent/ES2970282T3/es active Active
-
2020
- 2020-02-17 ZA ZA2020/00986A patent/ZA202000986B/en unknown
- 2020-04-08 CL CL2020000950A patent/CL2020000950A1/es unknown
- 2020-04-08 PH PH12020550241A patent/PH12020550241A1/en unknown
-
2023
- 2023-02-09 JP JP2023018050A patent/JP2023053087A/ja active Pending
-
2024
- 2024-02-28 AU AU2024201332A patent/AU2024201332A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL273689B1 (en) | 2023-10-01 |
EP3695846A4 (en) | 2021-06-30 |
US20200352997A1 (en) | 2020-11-12 |
CN111163758A (zh) | 2020-05-15 |
CL2020000950A1 (es) | 2020-08-14 |
JP7232447B2 (ja) | 2023-03-03 |
IL305898A (en) | 2023-11-01 |
BR112020006746A2 (pt) | 2020-10-06 |
RU2020113588A (ru) | 2021-11-12 |
TW201927314A (zh) | 2019-07-16 |
IL273689A (en) | 2020-05-31 |
PH12020550241A1 (en) | 2021-02-15 |
IL305898B1 (en) | 2024-05-01 |
EP3695846B1 (en) | 2023-11-29 |
EP4265634A2 (en) | 2023-10-25 |
EP4265634A3 (en) | 2024-01-24 |
SG11202003252TA (en) | 2020-05-28 |
ES2970282T3 (es) | 2024-05-27 |
JPWO2019073973A1 (ja) | 2020-11-05 |
AU2018349889B2 (en) | 2024-02-08 |
US11617765B2 (en) | 2023-04-04 |
IL273689B2 (en) | 2024-02-01 |
WO2019073973A1 (ja) | 2019-04-18 |
RU2020113588A3 (es) | 2021-12-13 |
AU2018349889A1 (en) | 2020-04-02 |
CA3075886A1 (en) | 2019-04-18 |
ZA202000986B (en) | 2024-04-24 |
JP2023053087A (ja) | 2023-04-12 |
EP3695846A1 (en) | 2020-08-19 |
AU2024201332A1 (en) | 2024-03-21 |
KR20200068661A (ko) | 2020-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003737A (es) | Potenciador para celulas t o celulas b que tienen funcion de memoria, inhibidor de recurrencia de tumor maligno, e inductor para inducir la funcion de memoria en celulas t o celulas b. | |
JOP20220008A1 (ar) | مثبطات parp1 | |
MX2019007276A (es) | Composiciones y métodos para mejora o aumento de la producción de ifn tipo i. | |
CL2017001687A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina. | |
EA201790649A1 (ru) | Бензилзамещенные индазолы в качестве ингибиторов bub 1 | |
TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
CL2019000729A1 (es) | Proteínas de unión recombinantes y sus usos. | |
CY1116703T1 (el) | ΧΡΗΣΗ sGC ΔΙΕΓΕΡΤΩΝ, sGC ΕΝΕΡΓΟΠΟΙΗΤΩΝ, MOΝΩΝ ΚΑΙ ΣΕ ΣΥΝΔΥΑΣΜΟ ME PDE5 ΑΝΑΣΤΟΛΕΙΣ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΗΣ ΣΥΣΤΗΜΙΚΗΣ ΣΚΛΗΡΥΝΣΗΣ (SSc) | |
PH12019550249A1 (en) | Solid compositions for oral administration | |
EP4233840A3 (en) | Combinations of linagliptin and metformin | |
BR112015020290A2 (pt) | métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos | |
MX2016015092A (es) | Inhibidor de proliferacion de celulas madre cancerosas. | |
CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
CL2018002793A1 (es) | Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control | |
CO2019008385A2 (es) | Mezcla que contiene 3,4-dimetilpirazol y su uso | |
MX2020004058A (es) | Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos. | |
CL2021000950A1 (es) | Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717) | |
CL2020002424A1 (es) | Composiciones farmacéuticas anticancerígenas para terapia combinada | |
MX2021014310A (es) | Formulaciones de terlipressina. | |
CL2020000446A1 (es) | Nueva formulación para estabilizar la harina de pescado. | |
AR112217A1 (es) | Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
EA201992200A1 (ru) | Микроинкапсулированные композиции ингибиторов нитрификации | |
AR111003A1 (es) | Arn terapéutico | |
ZA201907789B (en) | Solid compositions for oral administration |